Nicox Biotech Stock Jumps Over 7% Following Regulatory Green Light in China
The biotech company from Biot (Alpes-Maritimes) sees a significant uptick in mid-morning trading on the Paris Stock Exchange. The stock is reacting to a major regulatory breakthrough achieved by its Chinese partner for the antiglaucoma eye drops, its flagship asset. The session is part of a generally rising Parisian market.
Chinese Regulator's Approval Propels Stock Towards €0.51 Resistance
Nicox's stock has risen 6.23% to €0.3920, buoyed by the favorable opinion from the Chinese Center for Drug Evaluation (CDE) obtained by Ocumension Therapeutics on NCX 470. The exclusive partner of the biotech in the Chinese market can now file for market authorization for this eye drop intended for the treatment of glaucoma, as detailed in the press release published this Thursday. This regulatory step potentially paves the way for commercialization in China.
The rebound of the day brings the weekly performance to nearly 11%, after a decline of 7.2% over three months. The annual increase now exceeds 74%, reflecting the gradual improvement of the stock since last summer.
Above All Its Moving Averages, The Stock Aims for the €0.51 Resistance
The session's surge has pushed the price above the three moving averages monitored by traders, with a gap of nearly 6% over the MM20 (€0.37) and the MM200 (€0.37), while the MM50 (€0.39) has just been surpassed. The RSI at 44 remains in the neutral zone, leaving room before reaching an overbought configuration, while the next technical high is at €0.51. The support at €0.35, tested several times in recent months, serves as a reference floor.
On the agenda, the ordinary and extraordinary general meeting is scheduled for June 24, 2026. The commercial realization of NCX 470 in China will depend on the timeline for the review of the file by health authorities.
